A
Arbor Bio is a next-generation gene editing company focused on discovering and developing potentially curative genomic medicines, with the most extensive toolbox of proprietary genomic editors in the industry. We have the unique ability to work backward from disease pathology and choose the optimal editors or combination of editors for the disease in question.
Investor insights
Funding rounds participated in
$215M sweet spot round size
Investor type
Privately Held
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
2016
Funding rounds raised
Total raised
$215M
from 3 investors over 1 rounds
A
Arbor Biotechnologies raised $215M on December 9, 2021
Investors: Temasek Holdings, Ally Bridge Group and + 17 Other investors